2013
DOI: 10.3413/nukmed-0510-12-06
|View full text |Cite
|
Sign up to set email alerts
|

Patients with recurrent glioblastoma multiforme

Abstract: In this initial experience, treatment of GBM with (131)IPA in combination with EBRT was demonstrated to be safe and well tolerated, but less effective than suggested by the animal studies.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
8
0

Year Published

2015
2015
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 12 publications
(9 citation statements)
references
References 21 publications
1
8
0
Order By: Relevance
“…Therefore, we thought that para-211 At-PA uptake could be more specific to system L amino acid transporters. In addition, para-iodo-Lphenylalanine labelled with 123 I/ 131 I has been reported to show high uptake in glioma patients [7][8][9], suggesting the best coupling to be para-iodo/astato-L-phenylalanine.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Therefore, we thought that para-211 At-PA uptake could be more specific to system L amino acid transporters. In addition, para-iodo-Lphenylalanine labelled with 123 I/ 131 I has been reported to show high uptake in glioma patients [7][8][9], suggesting the best coupling to be para-iodo/astato-L-phenylalanine.…”
Section: Discussionmentioning
confidence: 99%
“…The derivative labelled with the gamma emitting isotope, para-123 I-iodo-L-phenylalanine ( 123 I-IPA), has been used with some success as a diagnostic imaging agent in glioblastoma patients [7]. The corresponding 131 I derivative ( 131 I-IPA) has been studied as a therapeutic agent, and is currently being advanced as a combination therapy with external beam radiation in a PhaseI/II clinical trial [8,9]. These PA-based compounds exhibit characteristics of high tumor to normal brain ratio that would be ideal for a targeted alpha therapeutic strategy.…”
Section: Research Papermentioning
confidence: 99%
“…Four of the studies summarized in Table 2 were investigated in a German framework for radiation research. Herein, the same therapeutic antibody [cetuximab (Erbitux®, Merck KGaA, Darmstadt, Germany) labelled with 90 Y], and the same panel of head and neck squamous cell carcinoma (HNSCC) cell lines were used. This offers the possibility 65 showed 2 years later that UT-SCC-5 also did not respond to CIERT when compared with EBRT alone in a tumour control analysis in xenografts.…”
Section: Pre-clinical Results: Promises and Challenges Of Combinationmentioning
confidence: 99%
“…However, different correction methods allow improved quantitative imaging. 50 Moreover, for the application of 90 Y-labelled radiopharmaceuticals, it is suggested to estimate the uptake and dosimetry with the nuclide counterpart 86 Y. 36 Nevertheless, 86 Y-PET is far from clinical routine, at least in the near future.…”
Section: Combination Of Internal and External Radiotherapymentioning
confidence: 99%
See 1 more Smart Citation